

Date of submission: 8th February 2023

To,
The Secretary
To,

The Secretary
Listing Department

The Secretary
Listing Department

BSE Limited National Stock Exchange of India Limited

Department of Corporate Services Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Mumbai – 400 051

Dalal Street, Mumbai – 400 001 Scrip Code- NH

Dear Sir/Madam,

Scrip Code - 539551

Sub: Investor Presentation for the Quarter and nine months ended 31st December 2022

With reference to the subject, please find enclosed Investor Presentation for the Quarter and nine months ended 31st December 2022.

Kindly take the above information on record.

Thanking you.

Yours faithfully

For Narayana Hrudayalaya Limited

Sridhar S.

Group Company Secretary, Legal & Compliance Officer

Encl.: as above



Investor Presentation

February 2023



Important Disclosure

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment.

Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions in India.

This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation can not be copied and/or disseminated in any manner.



NH at a Glance

As on 1st January 2023

A

47	Healthcare Facilities	Operational beds
19	Owned / Operated Hospitals ⁽¹⁾	5,462 Beds
2	Managed Hospitals ⁽²⁾	283 Beds
4	Heart Centres	266 Beds
21	Primary Healthcare Facilities ⁽³⁾	0 Beds
1	Hospital in Cayman Islands	110 Beds



6,373	Capacity Beds
6,121	Operational Beds
4.0 mn ⁽⁴⁾	Average Effective Capital Cost per Operational Bed



30+ Specialities




18.447

Full-time Employees and Associates including 3,970 doctors

(1) NH owns the P&L responsibility

- (2) NH manages 3rd party hospitals for Management Fees; including 1 project at St. Lucia
- (3) Includes clinics, information centres, etc.
- (4) Based on (Gross Block for Fixed Assets (adjusted for non-cash government grant provision impact, non-cash financial lease impact for Dharamshila unit, non-cash EPCG license impact)+ Capital Work in Progress (CWIP)) / Number of operational beds as of December 31st 2022 but excluding Managed Hospitals and Cayman facility
- * Includes operational beds of acquired Orthopedic and Trauma Hospital considered as part of MSMC Unit

NH's footprint in India





Key Highlights – Q3 FY23....(1/2)



Clinical & Operational

- Rabindranath Tagore International Institute of Cardiac Sciences (RTIICS), Kolkata has successfully conducted
 Robotic Partial Nephrectomy on a patient with Single Kidney
- Mazumdar Shaw Medical Centre (MSMC), Bengaluru performed highest number of Robotic Gynaecological Procedures for benign conditions. Achieved the milestone of 150 successful Complex Airway Reconstructions and touched about 1,500 patient base for complex aerodigestive anomalies & problems till date
- SRCC Children's Hospital, Mumbai achieved the highest quarterly volumes of 18 successful BMT procedures
- Narayana Multispeciality Hospital, Mysore performed some cutting-edge & complex clinical procedures in the
 Interventional radiology and GI Sciences segments in the quarter such as
 - TIPS procedure performed in view of Budd Chiari Syndrome
 - Laparoscopic Heller Cardiomyotomy with Toupet Fundoplication performed for achalasia cardia
 - HIPEC (Hyperthermic Intraperitoneal Chemotherapy) procedure



Financial Performance

- Consolidated operating revenues of INR 11,282 mn in Q3 FY23, an increase of 17.5% YoY
- Consolidated EBITDA of INR 2,660⁽¹⁾ mn in Q3 FY23 translating into EBITDA margin of 23.6% and consolidated PAT of INR 1,539 ⁽²⁾ mn at a PAT margin of 13.6%
- Consolidated Total Borrowings less Cash & Bank Balance and Current Investments of INR 2,142 mn as on 31st
 December, 2022 ie net debt to equity ratio of 0.11 (Out of which, debt worth US\$ 33 mn is foreign currency denominated)

⁽¹⁾ As per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 119 mn increase in EBITDA for Q3 FY23 and INR 409 mn increase in 9M FY23



Key Highlights – Q3 FY23(2/2)




- Implemented integration of Lab Sample Tracker into the NH Care Platform to enhance the patient experience to effortlessly track the status of patient samples and to get the real-time updates.
- Introduced a Payment Refund Tracker into the NH Care Platform to streamline the customer refund process and refund tracking mechanism
- Redesigned the "book tests" feature in the NH Care application to make it more user friendly and convenient to use.



- Achieved a net carbon reduction equivalent of 4,544 tonne through various energy optimization activities like using alternate energy, upgrade/replacement of equipment etc adopted across the network
- Achieved energy savings worth INR 11.0 mn across our units at Health City, Bengaluru and at Mysore through captive alternate energy sourcing channels
- Achieved savings worth INR 5.4 mn through upgradation of equipment across Health City at Bengaluru, RTIICS at Kolkata and Dharamshila at Delhi





Revenue Mix – India (Q3 FY23)





- (1) NH owns on freehold basis and operates with the P&L responsibility
- (2) NH operates the hospitals on rental/revenue sharing basis and owns the P&L responsibility
- (3) Includes managed hospital, clinics, learning and development, teleradiology, etc
- (4) As percentage of IP and OP revenue, excludes clinics and other ancillary business
- (5) Insured Patients include Insurance-covered patients, corporate patients (including public sector undertakings); Schemes include CGHS, ESIS, other state government schemes
- 6) Calculated on operating revenue of owned / operated hospitals
- (7) Percentages might not add upto 100% due to rounding off















- (1) OP figures include day-care business but does not include Vaccine footfalls
- (2) ARPOB for the period Q3 FY23 was INR 12.8 mn as against INR 11.7 mn in Q3 FY 22.
- (3) Footfalls for IP correspond to Discharges
- (4) Includes critical care and step-down care beds

Operational Review – Cayman Islands









- (1) OP figures include day-care business
- (2) ARPOB for the period Q3 FY 23 was USD 2.2 mn as compared to USD 2.0 mn in Q3 FY 22.
- (3) ALOS for the period Q3 FY23 was 9.6 days as compared to 8.2 days in Q3 FY22.

Regional Split – India (Q3 FY23)

This considers owned/operated hospitals in India (excl. Jammu (1))





⁽¹⁾ Jammu facility reported operational revenues of INR 311 mn and EBITDA of INR 22 mn in Q3 FY 23

^{*} Includes acquired Orthopedic and Trauma Hospital considered as part of MSMC Unit, effective from 1st October 2022



Profitability Snapshot – India





Categories have been calculated as

Consumable Expenses = Purchase of medical consumables, drugs and surgical equipment net of changes in inventories of medical consumables, drugs and surgical equipment; Manpower expenses = Employee benefits + Professional fees to doctors; Overhead expenses = All other expenses

⁽¹⁾ Denotes EBITDA for entire India business

⁽²⁾ Denotes EBITDA margin for entire India business



Consolidated Financial Performance

Figures in INR mn, unless stated otherwise

Profit and Loss Statement(1,3)

Particulars (INR mn)	Q3 FY23	9M FY23
Total Operating Revenue	11,282	33,032
Consumption	2,397	7,388
Doctors Expenses	2,172	6,451
Employee (Excluding Doctors) Expenses	1,967	5,803
Other Admin Expenses	2,202	6,489
Total Expenses	8,737	26,131
Other Income	116	508
EBITDA	2,660 ⁽⁴⁾	7,408 ⁽⁴⁾
Depreciation and Amortization	573	1,537
Finance Costs	187	489
Share of (loss)/profit of equity accounted investees	-	(2)
PBT	1,899	5,380
Tax Expense	360	1,047
PAT	1,539	4,334
Total Comprehensive Income	1,658	4,974

Particulars	31st December 2022
Shareholder Equity	19,653
Total Borrowings	7,758
Lease Liability	1,249
Net Block + CWIP	20,957(2)
Goodwill	799
Right to Use Assets	1,336
Net Receivables	4,449
Current Investments	1,671
Cash and Bank Balance	3,945

As on December 31st, 2022, the Total Borrowings less Cash & Bank Balance and Current Investments was INR 2,142 mn representing a net debt to equity ratio of 0.11 (Out of which, borrowings worth US\$ 33 mn is foreign currency denominated)


⁽¹⁾ Figures might not equal the reported numbers due to rounding off

⁽²⁾ Net Block includes non-cash government grant impact of INR 1,132 mn, non-cash financial lease impact of INR 754 mn and non-cash EPCG license impact of INR 39 mn

⁽³⁾ As per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 100 mn increase in depreciation, INR 18 mn increase in finance cost resulting in increase of INR 0.4 mn in PAT for Q3 FY 23 and INR 315 mn increase in depreciation, INR 86 mn increase in finance cost resulting in increase of INR 8.4 mn in PAT for 9M FY 23 on pre-IND AS 116 basis

⁽⁴⁾ Hospital project management in St. Lucia incurred an EBITDA loss of INR 13 mn in Q3 FY23 and loss of INR 108 mn in 9M FY23 as against operational loss of INR 20 mn in Q3 FY 22 and profit of INR 242 mn in 9M FY22






- (1) Cayman capex conversion rate of USD/INR is 81.0
- (2) Includes capex spend on bio medical equipment, civil face lifts and IT upgradation.
- (3) Expansion of existing facilities and installation of new capabilities across units
- (4) Inorganic acquisition e.g. Sparsh and other green field projects
- (5) Pertains to India

Shareholding Pattern





Total Number of Shares

204,360,804

Key DIIs

Axis Asset Management

Nippon Life India Asset Management

SBI Asset Management

ICICI Prudential Life Insurance

UTI Asset Management

Key Flls

Wellington Asset Management

Vanguard Index Fund

Mirae Asset Management

Simcah Partners

Franklin Templeton Asset Management